Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-blind, Multicentre, Placebo-controlled Study in Adults to Assess the Safety and Efficacy of Inhaled IBIO123, for Post-exposure Prophylaxis of COVID-19

NCT05639166 is registered in ClinicalTrials.gov with Immune Biosolutions Inc as lead sponsor.

NCT NCT05639166
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05639166 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-blind, Multicentre, Placebo-controlled Study in Adults to Assess the Safety and Efficacy of Inhaled IBIO123, for Post-exposure Prophylaxis of COVID-19
Lead sponsor
Immune Biosolutions Inc
Phase
Phase 2
Overall status
Completed
Start date
February 18, 2023
Completion date
May 16, 2023
Enrollment
200 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19